Lesson From Turing's Martin Shkreli: Pharmas Need To Walk Before They Can Talk

The rise and fall of Martin Shkreli over the past five months had no direct impact on the Boston business community, yet its impact on the biotech and drug development industry at the center of this area’s economy can’t be ignored.

I say that in part because several friends who have never shown any interest in what I do for a living have suddenly started caring about the drug development business.

Back to news